OC METRO CALENDAR

  • May 2012
    SuMoTuWeThFrSa
    293012345
    6789101112
    13141516171819
    20212223242526
    272829303112
    3456789
Add an event

MEDICAL TECHNOLOGY
Untitled Page Published: September 24, 2009 11:00 PM



Agendia, continued ...

MammaPrint is the first "in vitro diagnostic multivariate index assay" test (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA).  FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis and patients who are likely to develop metastases within five years following surgery.


“We are excited to be a part of Agendia’s continued growth and to enable the company to bolster its strategic marketing and sales efforts as it brings MammaPrint to an ever increasing number of breast cancer patients,” says Gertjan van der Baan, Board Member on behalf of van Herk Group, Agendia’s largest investor.


<< PREVIOUS PAGE

Related headlines
West Coast University expands to North Hollywood
Chapman report: Economic Forecast for the Legal Profession
UC Irvine nets $320,000 to expand free online initiative
Irvine’s Spectrum Pharmaceuticals raises $50 million
Orange County loses more than 6,000 jobs over the month